CL2021003081A1 - Polipéptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y métodos de uso (divisional de la solicitud no. 201903813) - Google Patents

Polipéptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y métodos de uso (divisional de la solicitud no. 201903813)

Info

Publication number
CL2021003081A1
CL2021003081A1 CL2021003081A CL2021003081A CL2021003081A1 CL 2021003081 A1 CL2021003081 A1 CL 2021003081A1 CL 2021003081 A CL2021003081 A CL 2021003081A CL 2021003081 A CL2021003081 A CL 2021003081A CL 2021003081 A1 CL2021003081 A1 CL 2021003081A1
Authority
CL
Chile
Prior art keywords
diseases
polypeptides
mtsp
inhibit
divisional
Prior art date
Application number
CL2021003081A
Other languages
English (en)
Inventor
Edwin L Madison
Vanessa Soros
Mikhail Popkov
Original Assignee
Catalyst Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalyst Biosciences Inc filed Critical Catalyst Biosciences Inc
Publication of CL2021003081A1 publication Critical patent/CL2021003081A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21109—Matriptase (3.4.21.109)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Materials For Photolithography (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan polipéptidos MTSP-1 modificados que tienen actividad y/o especificidad alterada de manera que escinden una proteína de complemento, tal como la proteína de complemento C3, para inhibir su actividad y por ello inhibir la activación de complemento. Los polipéptidos MTSP-1 modificados que inhiben la activación de complemento pueden usarse para el tratamiento de enfermedades y afecciones en las cuales la activación de complemento juega un papel. Tales enfermedades y afecciones incluyen enfermedades inflamatorias y enfermedades con un componente inflamatorio. Los ejemplos de estos trastornos son trastornos isquémicos y por reperfusión, incluyendo infarto al miocardio y apoplejía, sepsis, enfermedades autoinmunitarias, enfermedades oftálmicas, tales como retinopatías diabéticas y degeneración macular, incluyendo degeneración macular relacionada con la edad (AMD), y rechazo al órgano trasplantado, tal como función retardada de injerto renal (DGF).
CL2021003081A 2017-06-22 2021-11-22 Polipéptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y métodos de uso (divisional de la solicitud no. 201903813) CL2021003081A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762523735P 2017-06-22 2017-06-22
US201862664051P 2018-04-27 2018-04-27

Publications (1)

Publication Number Publication Date
CL2021003081A1 true CL2021003081A1 (es) 2022-08-12

Family

ID=63015005

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2019003813A CL2019003813A1 (es) 2017-06-22 2019-12-23 Polipéptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y métodos de uso.
CL2021003080A CL2021003080A1 (es) 2017-06-22 2021-11-22 Polipéptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y métodos de uso (divisional de la solicitud no. 201903813)
CL2021003081A CL2021003081A1 (es) 2017-06-22 2021-11-22 Polipéptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y métodos de uso (divisional de la solicitud no. 201903813)

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CL2019003813A CL2019003813A1 (es) 2017-06-22 2019-12-23 Polipéptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y métodos de uso.
CL2021003080A CL2021003080A1 (es) 2017-06-22 2021-11-22 Polipéptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y métodos de uso (divisional de la solicitud no. 201903813)

Country Status (18)

Country Link
US (5) US10781435B2 (es)
EP (1) EP3641801A1 (es)
JP (3) JP7091373B2 (es)
KR (1) KR102675270B1 (es)
CN (1) CN111107870A (es)
AU (2) AU2018290281B2 (es)
BR (1) BR112019027583A2 (es)
CA (2) CA3067851C (es)
CL (3) CL2019003813A1 (es)
CO (1) CO2020000584A2 (es)
IL (2) IL271587B2 (es)
JO (1) JOP20190288A1 (es)
MX (1) MX2019015402A (es)
NZ (1) NZ760116A (es)
PE (1) PE20200697A1 (es)
PH (1) PH12019502838A1 (es)
SG (3) SG10202110492YA (es)
WO (1) WO2018237201A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
CN111480345B (zh) 2017-12-14 2022-04-29 弗洛设计声能学公司 声泳系统及其操作方法、控制声换能器及声学系统的方法
US11396529B2 (en) * 2020-11-12 2022-07-26 National Sun Yat-Sen University Isolated peptide, anti-cancer medicinal composition including the same and method of specifically reducing or inhibiting activities of cancer cells using the same
AU2022205421A1 (en) * 2021-01-08 2023-07-20 Vertex Pharmaceuticals Incorporated Factor b proteases
CN113456527B (zh) * 2021-07-30 2023-04-07 北京清大赛尔生物科技有限公司 一种nadh微胶囊制剂及其制备方法和应用

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795A (en) 1848-09-19 Saddletree for carts
US5990A (en) 1848-12-26 of baltimore
US5324A (en) 1847-10-09 Cooking-stove
US844A (en) 1838-07-17 Boiler for
US237A (en) 1837-06-15 Egbert beale
US569A (en) 1838-01-09 Caruiag-e-spiiln g
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
DE3921528A1 (de) 1989-06-30 1991-01-10 Draegerwerk Ag Messzelle fuer den elektrochemischen gasnachweis
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
WO1994028024A1 (en) 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
CN1103782C (zh) 1994-03-31 2003-03-26 安姆根有限公司 单聚乙二醇化的mgdf多肽
US5795569A (en) 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6258351B1 (en) 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
ATE399809T1 (de) 1998-03-12 2008-07-15 Nektar Therapeutics Al Corp Verfahren zur herstellung von polymerkonjugaten
EP1095243A2 (en) 1998-07-03 2001-05-02 Neles Field Controls Oy Method and arrangement for measuring fluid
US6153394A (en) 1998-09-18 2000-11-28 Board Of Trustees Operating Michigan State University Immunoassay for equine protozoal myeloencephalitis in horses
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
AU7497000A (en) 1999-02-28 2000-11-14 Washington University Novel transduction molecules and methods for using same
CA2362670A1 (en) 1999-03-12 2000-09-14 Georgetown University Matriptase, a serine protease and its applications
PE20010288A1 (es) 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US6461802B1 (en) 1999-08-02 2002-10-08 Agfa-Gevaert Adhesive layer for polyester film
US7030231B1 (en) 1999-09-30 2006-04-18 Catalyst Biosciences, Inc. Membrane type serine protease 1 (MT-SP1) and uses thereof
WO2001032711A2 (en) 1999-10-21 2001-05-10 Board Of Trustees Of The University Of Arkansas Adeno-associated virus aav rep78 major regulatory protein, mutants thereof and uses thereof
KR100653153B1 (ko) 1999-12-22 2006-12-01 넥타르 테라퓨틱스 에이엘, 코포레이션 수용성 중합체의 입체장애 유도체
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
AU2001238595A1 (en) 2000-02-22 2001-09-03 Shearwater Corporation N-maleimidyl polymer derivatives
ATE367398T1 (de) 2000-05-16 2007-08-15 Bolder Biotechnology Inc Verfahren zur rückfaltung von proteinen mit freien cysteinresten
GB0103110D0 (en) 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
US7157596B2 (en) 2000-09-08 2007-01-02 Dendreon Corporation Inhibitors of serine protease activity of matriptase or MTSP1
DE60144439D1 (de) 2000-12-20 2011-05-26 Hoffmann La Roche Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
AU2002305052A1 (en) 2001-03-13 2002-09-24 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
US7105333B2 (en) 2001-03-27 2006-09-12 Deadreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
EP1539942A4 (en) 2001-05-14 2005-10-19 Dendreon Corp A TRANSMEMBRANE SERINE PROTEASE 10 CODING NUCLEIC ACID MOLECULES, THE POLYPEPTIDE CODED AND METHOD THEREOF
WO2002095007A2 (en) 2001-05-23 2002-11-28 Dendreon San Diego Llc Conjugates activated by cell surface proteases and therapeutic uses thereof
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
AU2002356824A1 (en) 2001-10-19 2003-05-06 The Scripps Research Institute Novel methods for introducing molecules into cells and vectors and compositions for use in such methods
US7026440B2 (en) 2001-11-07 2006-04-11 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7192468B2 (en) 2002-04-15 2007-03-20 Fluor Technologies Corporation Configurations and method for improved gas removal
AU2003269880A1 (en) 2002-05-21 2003-12-22 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 12, the encoded polypeptides and methods based thereon
EP2444809A3 (en) 2002-10-02 2013-07-24 Catalyst Biosciences, Inc. Methods of generating and screening for proteases with altered specificity
US20060024289A1 (en) 2002-10-02 2006-02-02 Ruggles Sandra W Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases
US7939304B2 (en) * 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
KR20040040782A (ko) 2002-11-08 2004-05-13 선바이오(주) 신규한 헥사-암 폴리에틸렌글리콜과 유도체 및 그의합성방법
EP2151507B1 (en) 2002-12-20 2013-02-13 Celera Corporation Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
US7019019B2 (en) 2002-12-23 2006-03-28 Dendreon Corporation Matriptase inhibitors and methods of use
US20040147027A1 (en) 2003-01-28 2004-07-29 Troy Carol M. Complex for facilitating delivery of dsRNA into a cell and uses thereof
US20060178297A1 (en) 2003-01-28 2006-08-10 Troy Carol M Systems and methods for silencing expression of a gene in a cell and uses thereof
AU2004215912B2 (en) 2003-02-26 2009-03-26 Nektar Therapeutics Polymer-factor VIII moiety conjugates
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
KR100512483B1 (ko) 2003-05-07 2005-09-05 선바이오(주) 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
KR101128320B1 (ko) 2003-05-23 2012-04-12 넥타르 테라퓨틱스 아미도카르보네이트 연결기를 갖는 ｐｅｇ 유도체
US7595306B2 (en) 2003-06-09 2009-09-29 Alnylam Pharmaceuticals Inc Method of treating neurodegenerative disease
CA2529752A1 (en) 2003-06-20 2005-09-15 The Regents Of The University Of California Polypeptide transduction and fusogenic peptides
US7439226B2 (en) 2003-09-30 2008-10-21 The United States Of America As Represented By The Department Of Health And Human Services Serine protease inhibitors
KR100956913B1 (ko) 2003-12-19 2010-05-11 제넨테크, 인크. 치료제로서 유용한 일가 항체 단편
CA2562729C (en) 2004-04-12 2013-11-12 Sandra Waugh Ruggles Cleavage of vegf and vegf receptor by wildtype and mutant mt-sp1
US8173144B2 (en) 2004-11-04 2012-05-08 L'oreal Administration of urea compounds for combating signs of cutaneous aging
EP1851543A2 (en) 2005-02-24 2007-11-07 Compugen Ltd. Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
AU2011218753B2 (en) * 2005-10-21 2013-10-24 Vertex Pharmaceuticals Incorporated Modified proteases that inhibit complement activation
NZ595193A (en) 2005-10-21 2013-09-27 Catalyst Biosciences Inc Modified Proteases That Inhibit Complement Activation
EP1940865A2 (en) 2005-11-01 2008-07-09 Arizona Board Regents, a body corporate of the State of Arizona, acting for and on behalf of Arizona State University Novel protein transduction domains and uses therefor
US7579318B2 (en) 2005-12-06 2009-08-25 Centre De La Recherche De La Scientifique Cell penetrating peptides for intracellular delivery of molecules
EP1991560B1 (en) 2006-02-20 2018-04-04 Ewha University-Industry Collaboration Foundation Peptide having cell membrane penetrating activity
EP1867661A1 (en) 2006-06-12 2007-12-19 Diatos Compositions and methods for delivering anti-activated ras antibodies into cells
CA2791144C (en) * 2006-07-05 2019-04-09 Catalyst Biosciences, Inc. Protease screening methods and proteases identified thereby
EP2046951B1 (en) 2006-07-05 2011-10-26 Catalyst Biosciences, Inc. Protease screening methods and proteases identified thererby
EP2427479B1 (en) 2009-05-07 2018-11-21 The Regents of The University of California Antibodies and methods of use thereof
WO2012021891A2 (en) 2010-08-13 2012-02-16 Tufts University Compositions, kits and methods for treatment of complement-related disorders
US20140329252A1 (en) 2011-10-14 2014-11-06 Hopital Sainte-Justine Methods and kits for diagnosing and/or prognosing osteoarthritis
CA2861066C (en) 2012-01-12 2024-01-02 Yale University Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
JP2015513913A (ja) 2012-04-02 2015-05-18 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ポリヌクレオチド
US10029415B2 (en) 2012-08-16 2018-07-24 Stratasys, Inc. Print head nozzle for use with additive manufacturing system
CA2836167A1 (en) 2013-12-10 2015-06-10 Christina Xiaolin Dai Thickness increase spring
AU2015254913B2 (en) 2014-04-29 2018-05-17 Novartis Ag Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest
TWI759810B (zh) 2014-08-08 2022-04-01 美商Ａｌｘ腫瘤技術股份有限公司 信號調節蛋白α(signal-regulatory proteinα, SIRP-α)變體構築物及其用途
EP3244907B1 (en) 2015-01-13 2020-02-19 City of Hope Ctla4-binding protein peptide-linker masks
AU2016209349B2 (en) 2015-01-20 2020-05-07 Arvinas, Inc. Compounds and methods for the targeted degradation of the Androgen Receptor
US11191844B2 (en) 2015-07-06 2021-12-07 Regeneran Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
US11903996B2 (en) 2015-10-07 2024-02-20 David C. Fritzinger Modulators of complement function
JP2018531983A (ja) 2015-11-02 2018-11-01 イエール ユニバーシティ タンパク質分解誘導キメラ化合物ならびにその調製方法および使用方法
BR112021012601A2 (pt) 2018-12-28 2021-11-30 Catalyst Biosciences Inc Polipeptídeos ativadores de plasminogênio do tipo uroquinase modificados e métodos de uso

Also Published As

Publication number Publication date
IL308949A (en) 2024-01-01
KR102675270B1 (ko) 2024-06-17
US11401513B2 (en) 2022-08-02
US11807882B2 (en) 2023-11-07
SG10202110492YA (en) 2021-11-29
US10781435B2 (en) 2020-09-22
NZ760116A (en) 2024-03-22
KR20200030063A (ko) 2020-03-19
JOP20190288A1 (ar) 2019-12-16
BR112019027583A2 (pt) 2020-10-06
CL2019003813A1 (es) 2020-05-29
AU2018290281B2 (en) 2021-12-16
CO2020000584A2 (es) 2020-05-05
JP7091373B2 (ja) 2022-06-27
CN111107870A (zh) 2020-05-05
AU2022201445B2 (en) 2023-11-23
SG11201912071QA (en) 2020-01-30
CA3067851A1 (en) 2018-12-27
CA3177086A1 (en) 2018-12-27
AU2022201445A1 (en) 2022-03-24
JP2020528742A (ja) 2020-10-01
US10954501B2 (en) 2021-03-23
US20210032617A1 (en) 2021-02-04
CL2021003080A1 (es) 2022-08-12
AU2018290281A1 (en) 2020-01-30
SG10202110500TA (en) 2021-11-29
US20240018502A1 (en) 2024-01-18
US20190093097A1 (en) 2019-03-28
IL271587B2 (en) 2024-05-01
CA3067851C (en) 2023-01-31
IL271587A (en) 2020-02-27
PE20200697A1 (es) 2020-06-16
PH12019502838A1 (en) 2020-09-21
IL271587B1 (en) 2024-01-01
WO2018237201A1 (en) 2018-12-27
MX2019015402A (es) 2020-07-20
JP2024095662A (ja) 2024-07-10
US20200291376A1 (en) 2020-09-17
JP2022120155A (ja) 2022-08-17
US20210355474A1 (en) 2021-11-18
EP3641801A1 (en) 2020-04-29

Similar Documents

Publication Publication Date Title
CL2021003080A1 (es) Polipéptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y métodos de uso (divisional de la solicitud no. 201903813)
EP4374851A3 (en) Ophthalmic composition for treatment of dry eye disease
SV2018005612A (es) Agentes, usos y metodos para el tratamiento de la sinucleinopatia
DOP2018000151A (es) Composiciones y métodos para disminuir la expresión de tau
PE20140982A1 (es) Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta
CL2009000400A1 (es) Compuestos heterociclicos derivados de 3-fenil-1,6- naftiridin-2-ona; moduladores de la actividad cinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastornos alergicos, trastornos autoinmunes, neoplasias, rechazo en trasplante de organos, entre otras.
CR20160311A (es) Nuevas pirazolil-heteroarilamidas como agentes plaguicidas
SA519410114B1 (ar) صيغ موضعية تحتوي على سيكلوسبورين واستخداماتها
UY35293A (es) Isotiazoles sustituidos con amino
CL2021003247A1 (es) Inhibidores de vía integrada para respuesta al estrés.
CL2019000640A1 (es) Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y métodos de uso.
MY197672A (en) Room temperature stable lyophilized protein
CL2020003447A1 (es) Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas
EA202091325A1 (ru) Способы лечения с помощью лигандов лантионин c-подобного белка 2 и подготовленных с их помощью клеток
CO2017000056A2 (es) Moléculas que tienen cierta utilidad plaguicida e intermediarios, composiciones y procedimientos relacionados con las mismas
CO2017002312A2 (es) Compuestos bicíclicos sustituidos
CO2021008338A2 (es) Polipéptidos de activador de plasminógeno, tipo urocinasa, modificados y métodos de uso
PE20171320A1 (es) Analogos de calcitonina para tratar enfermedades y trastornos
GT200600421A (es) Formas cristalinas polimórficas de la sal de di-sodio del ácido n-(5-clorosaliciloil)-8-aminocaprilico
MX2019014697A (es) Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn.
CO2019006843A2 (es) Uso de cry14 para el control de plagas de nematodos
EA202000017A1 (ru) Модифицированные пептиды сериновой протеазы 1 мембранного типа (mtsp-1) и способы применения
CO2018003596A2 (es) Arnip y su uso en métodos y composiciones para la inhibición de la expresión del gen nrarp
AR106477A1 (es) Combinación farmacéutica de antagonista del receptor nk3 y biguanidas
CO2020008885A2 (es) Arilsulfatasa a purificada y composiciones de la misma